LBPH - Hang Ten with this Positive Phase 1b/2a Clinical Trial Topline Data Announcement

2024-01-02 08:58:56 ET

DENVER, Colo., Jan. 2, 2024 ( www.247marketnews.com )- Longboard Pharmaceuticals Inc (NASDAQ: LBPH) reported, this morning, that it’s rapidly moving forward with preparations for its global Phase 3 program, after achieving positive topline data from the PACIFIC Study evaluating bexicaserin (LP352), a potentially best-in-class and highly selective, oral, novel 5-HT2C receptor superagonist for seizures associated with a broad range of Developmental and Epileptic Encephalopathies (DEEs), including favorable safety and tolerability results

Longboard Pharmaceuticals is trading at $12.764, up $6.734 (+111.67%), on 2.68M shares traded.

Its 52-week range is $3.395 to $10.29. It’s already well above its 52-week price and trading volume highs. It’s probably best to keep a tight mental stop loss, when the volume slows down.

24/7 MARKET NEWS, …

The post Hang Ten with this Positive Phase 1b/2a Clinical Trial Topline Data Announcement appeared first on 24/7 Market News .

For further details see: